anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
SCN8A developmental and epileptic encephalopathy (DEE) is a severe epilepsy syndrome resulting from mutations in the voltage-gated sodium channel Nav1.6, encoded by the gene SCN8A. Nav1.6 is expressed in excitatory and inhibitory neurons, yet previous studies primarily focus on how SCN8A mutations affect excitatory neurons, with limited studies on the importance of inhibitory interneurons. Parvalbumin (PV) interneurons are a prominent inhibitory interneuron subtype that expresses Nav1.6. To assess PV interneuron function within SCN8A DEE, we used 2 mouse models harboring patient-derived SCN8A gain-of-function variants, Scn8aD/+, where the SCN8A variant N1768D is expressed globally, and Scn8aW/+-PV, where the SCN8A variant R1872W is selectively expressed in PV interneurons. Expression of the R1872W SCN8A variant selectively in PV interneurons led to development of spontaneous seizures and seizure-induced death. Electrophysiology studies showed that Scn8aD/+ and Scn8aW/+-PV interneurons were susceptible to depolarization block and exhibited increased persistent sodium current. Evaluation of synaptic connections between PV interneurons and pyramidal cells showed synaptic transmission deficits in Scn8aD/+ and Scn8aW/+-PV interneurons. Together, our findings indicate that PV interneuron failure via depolarization block along with inhibitory synaptic impairment likely elicits an overall inhibitory reduction in SCN8A DEE, leading to unchecked excitation and ultimately resulting in seizures and seizure-induced death.
Human T-cell leukemia virus (HTLV-1) is the etiological agent of lymphoproliferative diseases such as adult T-cell leukemia and T-cell lymphoma (ATL) and a neurodegenerative disease known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). While several molecular clones of HTLV-1 have been published, all were isolated from samples derived from patients with adult T-cell leukemia. Here, we report the characterization of an HTLV-1 infectious molecular clone isolated from a sample of a patient with HAM/TSP disease. Genetic comparative analyses of the HAM/TSP molecular clone (pBST) revealed unique genetic alterations and specific viral mRNA expression patterns. Interestingly, our clone also harbors characteristics previously published to favor the development of HAM/TSP disease. The molecular clone is capable of infection and immortalization of human primary T cells in vitro. Our studies further demonstrate that the HTLV-1 virus produced from primary T cells transfected with pBST or ACH molecular clones cannot sustain long-term expansion, and cells cease to proliferate after 3-4 months in culture. In contrast, long-term proliferation and immortalization were achieved if the virus was transmitted from dendritic cells to primary T cells, and secondary infection of 729B cells in vitro was demonstrated. In both primary T cells and 729B cells, pBST and ACH were latent, and only hbz viral RNA was detected. This study suggests that HTLV-1 transmission from DC to T cells favors the immortalization of latently infected cells.
PURPOSE:The titled pharmaceutical, containing a 9,19-cyclolanostane derivative isolated as a component of Astragali Radix as an active constituent, capable of stimulating a host to promote the production of interferon, and useful as an antiviral and anticancer agent. CONSTITUTION:An inducing agent for interferon containing a compound expressed by formula I (R1 is OH or formula II; R2 is a group expressed by formula II or IV) as an active constituent. The compound expressed by formula I is obtained by extracting Astragali Radix with methanol, etc. under warming, distributing and transferring the resultant extract to another solvent i.e. benzene, etc. to remove impurities, distributing and transferring the resultant substance to another solvent i.e. n-butanol, and subjecting the resultant extract to the silica gel chromatogaphy (chloroform, methanol and water). The compound expressed by formula I has the ability to induce the interferon and can be administered orally or parenterally as a remedy for viral diseases, e.g. hepatitis or herpes, and cancers. The LD50 is 3,000mg/kg or more in mice for the compound expressed by formula I (R1 is formula II; R2 is formula III) by the intraperitoneal or oral route, and the toxicity is very low.
Patients undergo biopsy of one of their skin nodules prior to any treatment. Patients receive the Ad-p53 gene therapy in one nodule and injection of a second nodule with Dulbecco's phosphate buffered saline. The next day, patients begin chemotherapy, which may be given weekly and continues every 21-28 days for up to 6 courses. On day 3, patients return for biopsy of injected nodules. Biopsies are only performed during the first course. Patients may receive further injections of the Ad-p53 gene with subsequent courses of chemotherapy, for up to six courses.
Heart failure (HF) with reduced ventricular ejection fraction is a disease that affects around 5.7 million people in the United States, with a mortality rate of approximately 50% within 5 years. HF is characterized by an exacerbation of the renin-angiotensin-aldosterone system (RAAS), which leads to an increase in sympathetic nerve outflow, peripheral vasoconstriction, and reduced functional capacity. Moreover, many clinical trials have been developed for the treatment of HF patients focused on inhibition of RAAS, such as enalapril. Nevertheless, hospitalization and mortality rates in this population are excessive. However, studies with new drugs, such as the combination of valsartan/sacubitril, also known as LCZ696, have demonstrated important clinical impact on the morbidity and mortality outcomes in HF population. However, the effect of LCZ696 on the pathophysiological mechanisms of HF such as exercise tolerance (peak VO2) and peripheral muscle blood flow is not known. Since LCZ696 is a new drug with promising effects on the treatment of HF, the objective of the present study will be to evaluate the effect of LCZ696 in patients with HF on: 1) peak VO2, 2) 6-minute walk test, 3) peripheral muscle blood flow, 4) muscle strength, and 5) body composition.
Orthodontic patients, aged 11-18 who fulfill the inclusion/exclusion criteria and provide written informed consent to participate will undergo intra-oral scan. This will be repeated 2 weeks later.
(To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.)

Ciclopirox Topical Solution, 8%, (Nail Lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum. The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures.

  * No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended.
  * Ciclopirox Topical Solution, 8%, (Nail Lacquer), should be used only under medical supervision as described above.
  * The effectiveness and safety of Ciclopirox Topical Solution, 8%, (Nail Lacquer), in the following populations has not been studied. The clinical trials with use of Ciclopirox Topical Solution, 8%, (Nail Lacquer), excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded.
  * The safety and efficacy of using Ciclopirox Topical Solution, 8%, (Nail Lacquer), daily for greater than 48 weeks have not been established.
IA PRP procedure This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the suprapatellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
NEW MATERIAL:A glycerol glycoside shown by the formula I (R1 is acetyl, or group shown by the formula II; R2 is H, or group shown by the formula II; with the proviso that at least one of R1 and R2 is group shown by the formula II; R3 is OH). EXAMPLE:1-o-p-Coumaryl-3-o-beta-D-glucopyranosyl glycerol. USE:Useful as antifungal agent and antiviral agents for plants, inhibitor for eating against insects, field mice, etc., and plant growth regulator. Having humidifying action, and action to prevent chapped skin, useful as a material for cosmetic, and drugs. PROCESS:For example, the whole grass, preferably the bulb of Lilium regale Wilson, Lilium formosanum Wall, etc. is extracted with an extracting solvent such as water, methanol, etc. at room temperature or under heating, an extracted solution is partitioned with a partition solvent of a water-insoluble solvent and water, a collected water layer is partitioned to give a water-insoluble organic layer, which is subjected to column chromatography, and a bitter fraction is collected, to give a glycoside shown by the formula I .
The standard treatment for early-stage breast cancer involves breast-conserving surgery followed by adjuvant radiotherapy. However, approximately 20 % of patients experience distant metastasis, and adjuvant radiotherapy often leads to radiation-induced skin fibrosis (RISF). In this study, we develop an on-site injectable formulation composed of selenocystamine (SeCA) and hyaluronic acid (HyA), referred to as SeCA cross-linked HyA (SCH) agent, and investigate its potential to mitigate metastasis and prevent RISF associated with breast cancer therapy. SCH agents are synthesized using the nanoprecipitation method to modulate cell-cell tight junctions and tissue inflammation. The toxicity assessments reveal that SCH agents with a higher Se content (Se payload 17.4 μg/mL) are well tolerated by L929 cells compared to SeCA (Se payload 3.2 μg/mL). In vitro, SCH agents significantly enhance cell-cell tight junctions and effectively mitigate migration and invasion of breast cancer cells (4T1). In vivo, SCH agents mitigate distant lung metastasis. Furthermore, in animal models, SCH agents reduce RISF and promote wound repair. These findings highlight the potential of SCH agents as a novel therapeutic formulation for effectively mitigating metastasis and reducing RISF. This holds great promise for improving clinical outcomes in breast cancer patients undergoing adjuvant radiotherapy.
PURPOSE:To provide a magnetic compsn. which can be dosed within a living body by an injection method and is suitable mainly for the treatment of malignant tumors, etc., in hyperthermia by magnetism at a local point by distributing the compsn. to a specific lesion and near this part and the magnetic compsn. which can release drugs to the local point by magnetism. CONSTITUTION:This magnetic compsn. contains an amorphous alloy and a hydrophilic high polymer. The magnetic compsn. contains the amorphous alloy, the hydrophilic high polymer and the drugs.
A vital-signs patch for a patient monitoring system is disclosed. The patch consists of a housing that is configured to be worn on the skin of a patient. The housing contains a radio, one or more sensor interfaces, a processor, and a battery. The processor can selectably turn portions of the processor off and on and selectably turn power off and on to at least a portion of the sensor interfaces and radio. The processor includes a timer that, each time the timer times out, will turn all the parts of the processor on and start a new timing period. When the processor receives a signal, the processor will turn off power to at least a portion of the processor and at least a portion of the sensor interfaces.
Subjects aged between 18 and 47 months received the Fluarix™ vaccine. "Primed" subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the Fluarix-Primed Group) received 1 dose of Fluarix™ vaccine at Day 0. "Unprimed" subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the Fluarix-Unprimed Group) received 2 doses of Fluarix™ vaccine at Days 0 and 28. The Fluarix™ vaccine was administered intramuscularly in the deltoid of the right arm.
PCT No. PCT/US94/13188 Sec. 371 Date May 16, 1996 Sec. 102(e) Date May 16, 1996 PCT Filed Nov. 21, 1994 PCT Pub. No. WO95/14780 PCT Pub. Date Jun. 1, 1995Human monoclonal antibodies against a human cytokine (such as a human interleukin, e.g., human IL-1 alpha ) and fragments of such antibodies are disclosed. Also disclosed are pharmaceutical compositions and methods employing the human monoclonal antibodies and fragments, methods for screening for human monoclonal antibodies against a human protein, methods for producing a cDNA library enriched in DNA encoding VH and/or VL chains of a human monoclonal antibody, cell lines for making the human monoclonal antibodies, and isolated DNA for making the human monoclonal antibodies and fragments of the invention.
This is a Phase I safety study. There is only one arm of FOLFIRI administered every 14 days (2 week schedule) and sorafenib administered orally, twice daily continuously. First cycle sorafenib began at day +2 to FOLFIRI.
PURPOSE: The prevalence of epilepsy in patients with multiple sclerosis (MS) is three to six times the prevalence in the general population. Mechanisms resulting in increased seizure risk are not fully understood. Our objective is to characterize patients with MS and epilepsy regarding timing of diagnoses, MS and seizure (SZ) type, EEG findings suggesting cortical dysfunction, frequency of status epilepticus (SE), and seizure freedom.
METHODS: This was a single center retrospective study. Cases were obtained via DataDirect via the University of Michigan electronic medical record from January 1, 2006 through October, 12, 2016. The University of Michigan Health System is a large academic institute with a tertiary referral center and an Autoimmunity Center of Excellence. Patients were included if chart listed one or more of the top 62 epilepsy, and one or more of the top 2 MS, most frequently entered ICD9 and ICD10 codes. Patients with alternative epilepsy etiology were excluded. 74 of 361 patients were included. We collected information regarding demographics, MS and SZ type, age at diagnosis, imaging, EEG, seizure freedom, medications, and SE.
RESULTS: We found a high percentage of patients with SE. Most patients with imaging had multiple lesions at seizure onset. 27/54 of patients with EEG data showed electrographic evidence of cortical dysfunction. 6/8 of EEGs in PPMS showed features consistent with cortical dysfunction, followed by 9/17 in SPMS and 11/23 in RRMS. 7/8 of patients with PPMS showed EEG evidence of temporal lobe dysfunction.
CONCLUSION: Time of seizure onset relative to MS diagnosis varied with MS type suggesting distinct pathophysiology. EEG results correspond with reports of increased cortical damage and temporal dysfunction in PPMS, but are unique as a functional modality (EEG) as indicator of gray matter dysfunction. EEG findings differed in RRMS and progressive MS suggesting possibility of supportive diagnostic marker. Our data suggests higher risk of SE in progressive MS and diminished rate of seizure freedom for MS patients with SE. We conclude that early treatment with antiseizure medication would be beneficial for MS patients with SE and with progressive MS forms and SZ, in agreement with previous studies.
Phospholipids (PL) are major components of cellular membranes and changes in PL metabolism have been associated with the pathogenesis of numerous diseases. Lysophosphatidylcholine (LPC) in particular, is a comparably abundant component of oxidatively damaged tissues. LPC originates from the cleavage of phosphatidylcholine (PC) by phospholipase A2 or the reaction of lipids with reactive oxygen species (ROS) such as HOCl. Another explanation of increased LPC concentration is the decreased re-acylation of LPC into PC. While there are also several other lysophospholipids, LPC is the most abundant lysophospholipid in mammals and will therefore be the focus of this review. LPC is involved in many physiological processes. It induces the migration of lymphocytes, fostering the production of pro-inflammatory compounds by inducing oxidative stress. LPC also "signals" via G protein-coupled and Toll-like receptors and has been implicated in the development of different diseases. However, LPCs are not purely "bad": this is reflected by the fact that the concentration and fatty acyl composition of LPC varies under different conditions, in plasma of healthy and diseased individuals, in tissues and different tumors. Targeting LPC and lipid metabolism and restoring homeostasis might be a potential therapeutic method for inflammation-related diseases.
The invention discloses an artesunate and L-arginine composition for injection. The artesunate and L-arginine composition comprises the following components in parts by weight: 1,000 parts of artesunate as a raw material and 450-900 parts of L-arginine as an auxiliary material. According to the composition, the artesunate which is poor in solubility can be dissolved; the pH value can be adjusted to be neutral to slightly alkaline for injection; the solution is clear, transparent and colorless; the composition has good solubility and mobility, and can be sub-packaged into a practical powder preparation for injection; and more importantly, the stability of the composition is improved beyond thought. The invention also provides a preparation process of the artesunate and L-arginine composition for injection. The preparation method comprises the following steps: directly mixing the raw materials, namely artesunate and L-arginine; sub-packaging, or dissolving and degerming firstly and then preparing powder for injection by adopting a freeze-drying technology. The artesunate and L-arginine composition for injection disclosed by the invention is simple in preparation process and stable and reliable in quality.
Rationale: Psychological resilience (the ability to thrive in adversity) may protect against mental-health symptoms in healthcare professionals during coronavirus disease (COVID-19) waves. Objectives: To identify determinants of resilience in ICU staff members. Methods: In this cross-sectional survey in 21 French ICUs, staff members completed the 10-item Connor-Davidson Resilience Scale, Hospital Anxiety and Depression Scale, and Impact of Event Scale-Revised (for post-traumatic stress disorder [PTSD]). Factors independently associated with resilience were identified. Measurements and Main Results: The response rate was 73.1% (950 of 1,300). The median 10-item Connor-Davidson Resilience Scale score was 29 (interquartile range, 25-32). Symptoms of anxiety, depression, and PTSD were present in 61%, 39%, and 36% of staff members, respectively. Distress associated with the COVID-19 infodemic was correlated with symptoms of depression and PTSD. More resilient respondents less often had symptoms of anxiety, depression, and PTSD. Greater resilience was independently associated with male sex, having provided intensive care during the early waves, having managed more than 50 patients with COVID-19, and, compared with earlier waves, working longer hours, having greater motivation, and more often involving families in end-of-life decisions. Independent risk factors for lower resilience were having managed more than 10 patients who died of COVID-19, having felt frightened or isolated, and greater distress from the COVID-19 infodemic. Conclusions: This study identifies modifiable determinants of resilience among ICU staff members. Longitudinal studies are needed to determine whether prior resilience decreases the risk of mental ill health during subsequent challenges. Hospital and ICU managers, for whom preserving mental well-being among staff members is a key duty, should pay careful attention to resilience.
PURPOSE: A novel microorganism Zooshikella rubidus which produces red colorant is provided to use in anticancer, antibacterial, functional natural dyeing. CONSTITUTION: A Zooshikella rubidus has Zooshikella rubidus profile or RFLP(Restriction fragment length polymorphism)DNA profile same as Zooshikella rubidus. The Zooshikella rubidus comprises 16rRNA comprising nucleotide sequence of sequence number 1. The Zooshikella rubidus is Zooshikella rubidus S1-1(KCTC 11448BP). The red colorant is prodigiosin, cycloprodigiosin, prodigiosin derivative or mixture thereof. The prodigiosin derivative is denoted by chemical formula 3. A composition for anticancer contains extract or culture extract of Zooshikella rubidus.
PURPOSE: Provided are a physiologically active substance separated from echinacea and its manufacturing method. The ethylacetate fraction of MeOH extract of echinacea root exhibits enhanced cytotoxicity to tumor cells and is thus effectively used in the production of a functional food having anticancer activity. CONSTITUTION: Stems and roots of echinacea are washed, extracted 10 times of methanol for 3 days at room temperature and centrifuged for 40min. The above procedure is repeated 3 times. Then, the supernatant is concentrated in a rotary distiller under reduced pressure, the methanol extract is successively fractioned, concentrated and stored in a freezer at -20deg.C. The root fraction exhibits higher cytotoxicity to tumor cells than the stem fraction at a low concentration(0.125mg/ml).
The present invention relates to a smartphone-based personal medical information collecting system. The smartphone-based personal medical information collecting system comprises: a medical institution server which encrypts and provides medical information; a National Health Insurance Service server which encrypts and provides personal medical information; another healthcare platform servers which encrypts and provides personal healthcare information; a personal medical device which encrypts and provides biometrics; a personal terminal which includes a smartphone, a smart pad, and a personal portable terminal, wherein the personal terminal includes a collection application collecting health information and other information; and a PHR platform server which is connected to the personal terminal through communication to transmit a healthcare record including a personal medical record, a biorhythm, and an exercise record. To protect the personal information, the personal medical record is collected using a user's smartphone and stored in a personal health record (PHR) platform. Information to be collected includes medical records from a medical institution, health examination records from the National Health Insurance Service, life logs from the other healthcare platform (Google, Apple, Samsung), and records measured by the personal medical device. Log-in information to be collected of a the system is encrypted and stored in a personal smartphone. The collection application stores only a personal medical record collected into the PHR platform. The personal medical record stored in the PHR platform is used for various healthcare services.